Get started
AbbVie Inc.AbbVie Inc.AbbVie Inc.

AbbVie Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options Bonds

ABBV chart


Full chart

Key facts today

AbbVie Inc. saw a 15.2% rise in market cap due to strong sales of its immunology drugs—Humira, Skyrizi, and Rinvoq—totaling nearly $7 billion in Q2 2024.
Analyze the impactAnalyze the impact

ABBV upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪354.33 B‬ USD
Dividend yield (indicated)
3.29%
Price to earnings Ratio (TTM)
69.93
Basic EPS (TTM)
2.87 USD
Net income (FY)
‪4.82 B‬ USD
Revenue (FY)
‪54.32 B‬ USD
Shares float
‪1.76 B‬
Beta (1Y)
−0.12

Employees


Employees (FY)
‪50 K‬
Change (1Y)
0
Revenue / Employee (1Y)
‪1.09 M‬ USD
Net income / Employee (1Y)
‪96.40 K‬ USD

About AbbVie Inc.


Sector
Health Technology
CEO
Robert A. Michael
Headquarters
North Chicago
Website
abbvie.com
Founded
2011
FIGI
BBG0025Y4RY4
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ABBV news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ABBV highest yielding bonds


A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
6.90%
Maturity date
Jun 15, 2044
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
6.87%
Maturity date
Oct 1, 2042
A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
6.44%
Maturity date
Mar 15, 2045
A
ACT4218882
Allergan Funding SCS 4.55% 15-MAR-2035
Yield to maturity
5.75%
Maturity date
Mar 15, 2035
ABBV4911706
AbbVie Inc. 3.2% 21-NOV-2029
Yield to maturity
5.70%
Maturity date
Nov 21, 2029
ABBV5759196
AbbVie Inc. 5.5% 15-MAR-2064
Yield to maturity
5.39%
Maturity date
Mar 15, 2064
ABBV5068388
AbbVie Inc. 4.625% 01-OCT-2042
Yield to maturity
5.37%
Maturity date
Oct 1, 2042
ABBV5759195
AbbVie Inc. 5.4% 15-MAR-2054
Yield to maturity
5.28%
Maturity date
Mar 15, 2054
ABBV4693583
AbbVie Inc. 4.875% 14-NOV-2048
Yield to maturity
5.27%
Maturity date
Nov 14, 2048
4ABB
ABBVIE 15/45
Yield to maturity
5.27%
Maturity date
May 14, 2045
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044
Yield to maturity
5.24%
Maturity date
Jun 15, 2044

Explore more bonds 

Sparks


Curated watchlists where ABBV is featured.

See all sparks 

Frequently Asked Questions


The current price of ABBV is 199.50 USD — it has decreased by −0.01% in the past 24 hours. Watch AbbVie Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange AbbVie Inc. stocks are traded under the ticker ABBV.
ABBV stock has fallen by −1.90% compared to the previous week, the month change is a 3.96% rise, over the last year AbbVie Inc. has showed a 41.49% increase.
We've gathered analysts' opinions on AbbVie Inc. future price: according to them, ABBV price has a max estimate of 240.00 USD and a min estimate of 170.00 USD. Watch ABBV chart and read a more detailed AbbVie Inc. stock forecast: see what analysts think of AbbVie Inc. and suggest that you do with its stocks.
ABBV reached its all-time high on Oct 31, 2024 with the price of 207.32 USD, and its all-time low was 32.51 USD and was reached on Dec 17, 2012. View more price dynamics on ABBV chart.
See other stocks reaching their highest and lowest prices.
ABBV stock is 1.21% volatile and has beta coefficient of −0.12. Track AbbVie Inc. stock price on the chart and check out the list of the most volatile stocks — is AbbVie Inc. there?
Today AbbVie Inc. has the market capitalization of ‪352.54 B‬, it has increased by 6.25% over the last week.
Yes, you can track AbbVie Inc. financials in yearly and quarterly reports right on TradingView.
AbbVie Inc. is going to release the next earnings report on Jan 29, 2025. Keep track of upcoming events with our Earnings Calendar.
ABBV earnings for the last quarter are 3.00 USD per share, whereas the estimation was 2.92 USD resulting in a 2.74% surprise. The estimated earnings for the next quarter are 2.97 USD per share. See more details about AbbVie Inc. earnings.
AbbVie Inc. revenue for the last quarter amounts to ‪14.46 B‬ USD, despite the estimated figure of ‪14.28 B‬ USD. In the next quarter, revenue is expected to reach ‪14.79 B‬ USD.
ABBV net income for the last quarter is ‪1.55 B‬ USD, while the quarter before that showed ‪1.36 B‬ USD of net income which accounts for 14.04% change. Track more AbbVie Inc. financial stats to get the full picture.
Yes, ABBV dividends are paid quarterly. The last dividend per share was 1.55 USD. As of today, Dividend Yield (TTM)% is 3.11%. Tracking AbbVie Inc. dividends might help you take more informed decisions.
AbbVie Inc. dividend yield was 3.87% in 2023, and payout ratio reached 220.33%. The year before the numbers were 3.53% and 86.17% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 9, 2024, the company has ‪50.00 K‬ employees. See our rating of the largest employees — is AbbVie Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AbbVie Inc. EBITDA is ‪25.32 B‬ USD, and current EBITDA margin is 49.30%. See more stats in AbbVie Inc. financial statements.
Like other stocks, ABBV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AbbVie Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AbbVie Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AbbVie Inc. stock shows the buy signal. See more of AbbVie Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.